Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Remsima

This page shows the latest Remsima news and features for those working in and with pharma, biotech and healthcare.

Mundipharma adds breast cancer biosimilar to its portfolio with Celltrion deal

Mundipharma adds breast cancer biosimilar to its portfolio with Celltrion deal

This will be the third biosimilar Mundipharma and Celltrion has launched in the EU, following Remsima (infliximab) and Truxima (rituximab), biosimilars of Johnson and Johnson’s Remicade and Roche’s MabThera. ... With Remsima, we achieved market

Latest news

  • Biosimilars eat into J&J's Remicade sales Biosimilars eat into J&J's Remicade sales

    competition from Pfizer's Inflectra, Mundipharma's Remsima and Samsung Bioepis' Renflexis/Flixabi.

  • Standing out in a crowd Standing out in a crowd

    Last year it won the first European and US approvals for a biosimilar version of the blockbuster arthritis treatment Remicade (infliximab), which is marketed under the brand names Remsima and Inflectra. ... patients that could have been switched from

  • Facing the new wave of biosimilars Facing the new wave of biosimilars

    NOR-SWITCH is a randomised, double-blind study of nearly 500 patients, designed to evaluate the effects of a single switch from an original biologic (Remicade) to its biosimilar (Remsima) across

  • Mundipharma to launch first MabThera biosimilar in EU Mundipharma to launch first MabThera biosimilar in EU

    Truxima is not the first biosimilar Mundipharma has licensed for EU marketing, having launched Remsima, a biosimilar version of Janssen's blockbuster arthritis treatment Remicade (infliximab), in 2015.

  • NOR-SWITCH - the final piece in the biosimilar puzzle? NOR-SWITCH - the final piece in the biosimilar puzzle?

    Remsima, called Inflectra in some regions) across six inflammatory diseases for which infliximab is approved. ... Remsima. This matters because the biologic and each biosimilar within a product class are similar but not identical to each other, and each

More from news
Approximately 3 fully matching, plus 20 partially matching documents found.

Latest Intelligence

  • The reality of real-world evidence The reality of real-world evidence

    RWE data presented at ECCO this year showed that switching to the biosimilar Remsima (infliximab) from the originator had no negative effect on safety and efficacy in 10 real-world studies.

  • Biosimilars - the same, but different? Biosimilars - the same, but different?

    This first infliximab biosimilar was developed and manufactured by Celltrion and is marketed by various partners, notably Hospira under the brand name Inflectra and Mundipharma as Remsima. ... Meanwhile, as Europe focuses on the market debuts of

  • Biosimilars: friend or foe for healthcare systems? Biosimilars: friend or foe for healthcare systems?

    products in development (see chart overleaf), with Remsima/Inflectra the only biosimilar mentioned specifically by name. .

  • An eye towards the biobetter in South Korea An eye towards the biobetter in South Korea

    Celltrion received approval by the Korean Food &Drug Administration (KFDA) for Remsima in July 2012 and also filed for approval in the EU and other countries in the same year. ... Remsima was recently added to the list. Looking forward, there are likely

More from intelligence
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest from PMHub

  • The Biosimilar Challenge

    These include the infliximab biosimilars Inflectra and Remsima, the etanercept biosimilar Benepali (launched last year) and biosimilars to adalimumab, filgrastim and bevacizumab preparing to launch on the horizon. .

  • Infographic: RA Perceptions

    Physicians predict a four-fold increase in their use of Hospira’s Inflectra and Celltrion’s Remsima.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Quick links

Infographics

Multimedia